Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer

Jorianne Boers; Carolina P Schröder; Geke A P Hospers; Erik F J de Vries; Andor W J M Glaudemans

doi:10.1097/RLU.0000000000003382

Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer

Jorianne Boers^*, Carolina P Schröder, Geke A P Hospers, Erik F J de Vries, Andor W J M Glaudemans

^*Corresponding author voor dit werk

Onderzoeksoutput: Article › Academic › peer review

8 Citaten (Scopus)

157 Downloads (Pure)

Samenvatting

We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.

Originele taal-2	English
Pagina's (van-tot)	e165-e167
Aantal pagina's	3
Tijdschrift	Clinical Nuclear Medicine
Volume	46
Nummer van het tijdschrift	3
Vroegere onlinedatum	10-nov.-2020
DOI's	https://doi.org/10.1097/RLU.0000000000003382
Status	Published - mrt.-2021

Toegang tot document

10.1097/RLU.0000000000003382

Detection_of_Dural_Metastases_Before_the_Onset_of.96373Final publisher's version, 296 KBLicentie: Taverne

Handle.net

Permanente koppeling

Citeer dit

@article{6ce7ec7f0c8a467a9982d459fc9dd872,

title = "Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer",

abstract = "We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.",

keywords = "[F-18]-FES PET, brain metastases, breast cancer, estrogen receptor",

author = "Jorianne Boers and Schr{\"o}der, {Carolina P} and Hospers, {Geke A P} and {de Vries}, {Erik F J} and Glaudemans, {Andor W J M}",

year = "2021",

month = mar,

doi = "10.1097/RLU.0000000000003382",

language = "English",

volume = "46",

pages = "e165--e167",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer

AU - Boers, Jorianne

AU - Schröder, Carolina P

AU - Hospers, Geke A P

AU - de Vries, Erik F J

AU - Glaudemans, Andor W J M

PY - 2021/3

Y1 - 2021/3

N2 - We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.

AB - We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.

KW - [F-18]-FES PET

KW - brain metastases

KW - breast cancer

KW - estrogen receptor

U2 - 10.1097/RLU.0000000000003382

DO - 10.1097/RLU.0000000000003382

M3 - Article

C2 - 33181752

SN - 0363-9762

VL - 46

SP - e165-e167

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 3

ER -

Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit